{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:36:21Z","timestamp":1787668581022,"version":"build-2736575974"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00702-018-1869-1","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T03:10:09Z","timestamp":1520392209000},"page":"1237-1250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia"],"prefix":"10.1007","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-6512","authenticated-orcid":false,"given":"Santiago","family":"Perez-Lloret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"1869_CR1","unstructured":"Adamas Pharmaceuticals (2017) Summary of product characteristics: Gocovri, amantadine extended-release. https:\/\/www.gocovri.com\/ . Accessed 02 Oct 2017"},{"issue":"3","key":"1869_CR2","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16(3):448\u2013458","journal-title":"Mov Disord"},{"issue":"1","key":"1869_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.expneurol.2004.08.030","volume":"191","author":"KA Allers","year":"2005","unstructured":"Allers KA, Bergstrom DA, Ghazi LJ, Kreiss DS, Walters JR (2005) MK801 and amantadine exert different effects on subthalamic neuronal activity in a rodent model of Parkinson\u2019s disease. Exp Neurol 191(1):104\u2013118. https:\/\/doi.org\/10.1016\/j.expneurol.2004.08.030","journal-title":"Exp Neurol"},{"key":"1869_CR4","unstructured":"Alliance Pharmaceuticals (2010) Summary of product characteristics: Symmetrel(R) capsules (amantadine hydrochloride 100\u00a0mg)"},{"issue":"3","key":"1869_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/WNF.0b013e3181900115","volume":"32","author":"H Alonso Navarro","year":"2009","unstructured":"Alonso Navarro H, Sanz-Aiz A, Izquierdo L, Jimenez Jimenez FJ (2009) Syndrome of inappropriate antidiuretic hormone secretion possibly associated with amantadine therapy in Parkinson disease. Clin Neuropharmacol 32(3):167\u2013168. https:\/\/doi.org\/10.1097\/WNF.0b013e3181900115","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"1869_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/00003088-198814010-00003","volume":"14","author":"FY Aoki","year":"1988","unstructured":"Aoki FY, Sitar DS (1988) Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 14(1):35\u201351. https:\/\/doi.org\/10.2165\/00003088-198814010-00003","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1869_CR7","doi-asserted-by":"publisher","first-page":"e52680","DOI":"10.1371\/journal.pone.0052680","volume":"8","author":"R Aron Badin","year":"2013","unstructured":"Aron Badin R, Spinnewyn B, Gaillard MC, Jan C, Malgorn C, Van Camp N, Dolle F, Guillermier M, Boulet S, Bertrand A, Savasta M, Auguet M, Brouillet E, Chabrier PE, Hantraye P (2013) IRC-082451, a novel multitargeting molecule, reduces l-DOPA-induced dyskinesias in MPTP Parkinsonian primates. PLoS ONE 8(1):e52680. https:\/\/doi.org\/10.1371\/journal.pone.0052680","journal-title":"PLoS ONE"},{"issue":"8","key":"1869_CR8","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/mds.25366","volume":"28","author":"E Bezard","year":"2013","unstructured":"Bezard E, Tronci E, Pioli EY, Li Q, Porras G, Bjorklund A, Carta M (2013) Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 28(8):1088\u20131096. https:\/\/doi.org\/10.1002\/mds.25366","journal-title":"Mov Disord"},{"issue":"2","key":"1869_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.expneurol.2005.08.017","volume":"196","author":"F Bibbiani","year":"2005","unstructured":"Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN (2005) Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 196(2):422\u2013429. https:\/\/doi.org\/10.1016\/j.expneurol.2005.08.017","journal-title":"Exp Neurol"},{"issue":"6","key":"1869_CR10","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/j.1471-4159.2011.07376.x","volume":"118","author":"S Bido","year":"2011","unstructured":"Bido S, Marti M, Morari M (2011) Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J Neurochem 118(6):1043\u20131055. https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07376.x","journal-title":"J Neurochem"},{"issue":"2","key":"1869_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1353-8020(98)00013-3","volume":"4","author":"W Birkmayer","year":"1998","unstructured":"Birkmayer W, Hornykiewicz O (1998) The effect of l-3,4-dihydroxyphenylalanine (=\u2009DOPA) on akinesia in parkinsonism. Parkinsonism Relat Disord 4(2):59\u201360","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"1869_CR12","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/mds.870130507","volume":"13","author":"PJ Blanchet","year":"1998","unstructured":"Blanchet PJ, Konitsiotis S, Chase TN (1998) Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 13(5):798\u2013802. https:\/\/doi.org\/10.1002\/mds.870130507","journal-title":"Mov Disord"},{"issue":"13","key":"1869_CR13","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1523\/JNEUROSCI.4262-04.2005","volume":"25","author":"TA Blanpied","year":"2005","unstructured":"Blanpied TA, Clarke RJ, Johnson JW (2005) Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 25(13):3312\u20133322. https:\/\/doi.org\/10.1523\/JNEUROSCI.4262-04.2005","journal-title":"J Neurosci"},{"issue":"1","key":"1869_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12640-016-9618-4","volume":"30","author":"M Bortolanza","year":"2016","unstructured":"Bortolanza M, Bariotto-Dos-Santos KD, Dos-Santos-Pereira M, da-Silva CA, Del-Bel E (2016) Antidyskinetic effect of 7-nitroindazole and sodium nitroprusside associated with amantadine in a rat model of Parkinson\u2019s disease. Neurotox Res 30(1):88\u2013100. https:\/\/doi.org\/10.1007\/s12640-016-9618-4","journal-title":"Neurotox Res"},{"key":"1869_CR15","doi-asserted-by":"publisher","first-page":"426413","DOI":"10.1155\/2013\/426413","volume":"2013","author":"JT Boyd","year":"2013","unstructured":"Boyd JT, Silverman DA (2013) Amantadine-induced patulous eustachian tubes in Parkinson\u2019s disease. Case Rep Otolaryngol 2013:426413. https:\/\/doi.org\/10.1155\/2013\/426413","journal-title":"Case Rep Otolaryngol"},{"issue":"3","key":"1869_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF00314331","volume":"236","author":"M Brenner","year":"1989","unstructured":"Brenner M, Haass A, Jacobi P, Schimrigk K (1989) Amantadine sulphate in treating Parkinson\u2019s disease: clinical effects, psychometric tests and serum concentrations. J Neurol 236(3):153\u2013156","journal-title":"J Neurol"},{"key":"1869_CR17","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2014.0184","author":"P Calabresi","year":"2015","unstructured":"Calabresi P, Ghiglieri V, Mazzocchetti P, Corbelli I, Picconi B (2015) Levodopa-induced plasticity: a double-edged sword in Parkinson\u2019s disease? Philos Trans R Soc Lond B Biol Sci. https:\/\/doi.org\/10.1098\/rstb.2014.0184","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"7","key":"1869_CR18","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nn.4306","volume":"19","author":"P Calabresi","year":"2016","unstructured":"Calabresi P, Pisani A, Rothwell J, Ghiglieri V, Obeso JA, Picconi B (2016) Hyperkinetic disorders and loss of synaptic downscaling. Nat Neurosci 19(7):868\u2013875. https:\/\/doi.org\/10.1038\/nn.4306","journal-title":"Nat Neurosci"},{"key":"1869_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12659\/ajcr.889931","volume":"15","author":"J Cattoni","year":"2014","unstructured":"Cattoni J, Parekh R (2014) Acute respiratory distress syndrome: a rare presentation of amantadine toxicity. Am J Case Rep 15:1\u20133. https:\/\/doi.org\/10.12659\/ajcr.889931","journal-title":"Am J Case Rep"},{"issue":"6","key":"1869_CR20","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.ophtha.2009.10.039","volume":"117","author":"KC Chang","year":"2010","unstructured":"Chang KC, Jeong JH, Kim MK, Wee WR, Lee JH, Jeon BS (2010) The effect of amantadine on corneal endothelium in subjects with Parkinson\u2019s disease. Ophthalmology 117(6):1214\u20131219. https:\/\/doi.org\/10.1016\/j.ophtha.2009.10.039","journal-title":"Ophthalmology"},{"issue":"10 Suppl","key":"1869_CR21","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/S1471-1931(00)00018-5","volume":"23","author":"TN Chase","year":"2000","unstructured":"Chase TN, Oh JD (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23(10 Suppl):S86\u2013S91","journal-title":"Trends Neurosci"},{"issue":"5","key":"1869_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","volume":"8","author":"KR Chaudhuri","year":"2009","unstructured":"Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8(5):464\u2013474","journal-title":"Lancet Neurol"},{"issue":"1","key":"1869_CR23","doi-asserted-by":"publisher","first-page":"112.e115","DOI":"10.1016\/j.ajem.2007.07.015","volume":"26","author":"PL Cheng","year":"2008","unstructured":"Cheng PL, Hung SW, Lin LW, Chong CF, Lau CI (2008) Amantadine-induced serotonin syndrome in a patient with renal failure. Am J Emerg Med 26(1):112.e115\u2013116.e115. https:\/\/doi.org\/10.1016\/j.ajem.2007.07.015","journal-title":"Am J Emerg Med"},{"issue":"7","key":"1869_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.parkreldis.2005.05.008","volume":"11","author":"FP Silva-Junior da","year":"2005","unstructured":"da Silva-Junior FP, Braga-Neto P, Sueli Monte F, de Bruin VM (2005) Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 11(7):449\u2013452. https:\/\/doi.org\/10.1016\/j.parkreldis.2005.05.008","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1869_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1023\/A:1008928321652","volume":"9","author":"AM Damiano","year":"2000","unstructured":"Damiano AM, McGrath MM, Willian MK, Snyder CF, LeWitt PA, Reyes PF, Richter RR, Means ED (2000) Evaluation of a measurement strategy for Parkinson\u2019s disease: assessing patient health-related quality of life. Qual Life Res 9(1):87\u2013100","journal-title":"Qual Life Res"},{"issue":"4","key":"1869_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/(SICI)1098-2396(19991215)34:4<313::AID-SYN7>3.0.CO;2-1","volume":"34","author":"P Deep","year":"1999","unstructured":"Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P (1999) Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 34(4):313\u2013318 ( https:\/\/doi.org\/10.1002\/(SICI)1098-2396(19991215)34:4<313:AID-SYN7>3.0.CO;2-1 )","journal-title":"Synapse"},{"issue":"1","key":"1869_CR27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","volume":"179","author":"A Dekundy","year":"2007","unstructured":"Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179(1):76\u201389. https:\/\/doi.org\/10.1016\/j.bbr.2007.01.013","journal-title":"Behav Brain Res"},{"issue":"3","key":"1869_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/mds.1112","volume":"16","author":"P Dotto Del","year":"2001","unstructured":"Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U (2001) Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 16(3):515\u2013520","journal-title":"Mov Disord"},{"issue":"4","key":"1869_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","volume":"41","author":"D Deleu","year":"2002","unstructured":"Deleu D, Northway MG, Hanssens Y (2002) Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson\u2019s disease. Clin Pharmacokinet 41(4):261\u2013309. https:\/\/doi.org\/10.2165\/00003088-200241040-00003","journal-title":"Clin Pharmacokinet"},{"issue":"24","key":"1869_CR30","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351(24):2498\u20132508","journal-title":"N Engl J Med"},{"issue":"8","key":"1869_CR31","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1517\/14740338.2014.931369","volume":"13","author":"MA Faulkner","year":"2014","unstructured":"Faulkner MA (2014) Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson\u2019s disease. Expert Opin Drug Saf 13(8):1055\u20131069. https:\/\/doi.org\/10.1517\/14740338.2014.931369","journal-title":"Expert Opin Drug Saf"},{"issue":"1\u20133","key":"1869_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF01345241","volume":"14","author":"A Fisher","year":"1998","unstructured":"Fisher A, Biggs CS, Starr MS (1998) Effects of glutamate antagonists on the activity of aromatic l-amino acid decarboxylase. Amino Acids 14(1\u20133):43\u201349","journal-title":"Amino Acids"},{"issue":"1\u20132","key":"1869_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejphar.2007.11.051","volume":"581","author":"M Foller","year":"2008","unstructured":"Foller M, Geiger C, Mahmud H, Nicolay J, Lang F (2008) Stimulation of suicidal erythrocyte death by amantadine. Eur J Pharmacol 581(1\u20132):13\u201318. https:\/\/doi.org\/10.1016\/j.ejphar.2007.11.051","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 3","key":"1869_CR34","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/mds.23829","volume":"26","author":"SH Fox","year":"2011","unstructured":"Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord 26(Suppl 3):S2\u201341. https:\/\/doi.org\/10.1002\/mds.23829","journal-title":"Mov Disord"},{"issue":"3","key":"1869_CR35","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/pra.0000000000000237","volume":"23","author":"LD Fryml","year":"2017","unstructured":"Fryml LD, Williams KR, Pelic CG, Fox J, Sahlem G, Robert S, Revuelta GJ, Short EB (2017) The role of amantadine withdrawal in 3 cases of treatment-refractory altered mental status. J Psychiatr Pract 23(3):191\u2013199. https:\/\/doi.org\/10.1097\/pra.0000000000000237","journal-title":"J Psychiatr Pract"},{"issue":"5","key":"1869_CR36","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1212\/WNL.50.5.1211","volume":"50","author":"CG Goetz","year":"1998","unstructured":"Goetz CG (1998) New lessons from old drugs: amantadine and Parkinson\u2019s disease. Neurology 50(5):1211\u20131212","journal-title":"Neurology"},{"issue":"3","key":"1869_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/mds.25321","volume":"28","author":"CG Goetz","year":"2013","unstructured":"Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S (2013) Which dyskinesia scale best detects treatment response? Mov Disord 28(3):341\u2013346. https:\/\/doi.org\/10.1002\/mds.25321","journal-title":"Mov Disord"},{"key":"1869_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27092","author":"CG Goetz","year":"2017","unstructured":"Goetz CG, Stebbins GT, Chung KA, Nicholas AP, Hauser RA, Merkitch D, Stacy MA (2017) Topiramate as an adjunct to amantadine in the treatment of dyskinesia in Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled multicenter study. Mov Disord. https:\/\/doi.org\/10.1002\/mds.27092","journal-title":"Mov Disord"},{"issue":"2","key":"1869_CR39","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0022-3565(24)34927-4","volume":"290","author":"KB Goralski","year":"1999","unstructured":"Goralski KB, Smyth DD, Sitar DS (1999) In vivo analysis of amantadine renal clearance in the uninephrectomized rat: functional significance of in vitro bicarbonate-dependent amantadine renal tubule transport. J Pharmacol Exp Ther 290(2):496\u2013504","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 3","key":"1869_CR40","doi-asserted-by":"publisher","first-page":"S560","DOI":"10.1002\/mds.22020","volume":"23","author":"AA Grace","year":"2008","unstructured":"Grace AA (2008) Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. Mov Disord 23(Suppl 3):S560\u2013S569. https:\/\/doi.org\/10.1002\/mds.22020","journal-title":"Mov Disord"},{"key":"1869_CR41","doi-asserted-by":"publisher","first-page":"467131","DOI":"10.1155\/2014\/467131","volume":"2014","author":"RA Hauser","year":"2014","unstructured":"Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, Rascol O, Debieuvre C, Frassdorf M (2014) Minimal clinically important difference in Parkinson\u2019s disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis 2014:467131. https:\/\/doi.org\/10.1155\/2014\/467131","journal-title":"Parkinsons Dis"},{"issue":"3","key":"1869_CR42","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3233\/jpd-171134","volume":"7","author":"RA Hauser","year":"2017","unstructured":"Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ (2017) ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 2 study): interim results of an open-label safety study. J Parkinsons Dis 7(3):511\u2013522. https:\/\/doi.org\/10.3233\/jpd-171134","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"1869_CR43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/0014-2999(72)90144-6","volume":"20","author":"RE Heikkila","year":"1972","unstructured":"Heikkila RE, Cohen G (1972) Evaluation of amantadine as a releasing agent or uptake blocker for H 3-dopamine in rat brain slices. Eur J Pharmacol 20(2):156\u2013160","journal-title":"Eur J Pharmacol"},{"issue":"5\u20136","key":"1869_CR44","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s007020050168","volume":"106","author":"MB Hesselink","year":"1999","unstructured":"Hesselink MB, De Boer AG, Breimer DD, Danysz W (1999) Adaptations of NMDA and dopamine D2, but not of muscarinic receptors following 14\u00a0days administration of uncompetitive NMDA receptor antagonists. J Neural Transm (Vienna) 106(5\u20136):409\u2013421. https:\/\/doi.org\/10.1007\/s007020050168","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"1869_CR45","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/jpet.104.066191","volume":"310","author":"MP Hill","year":"2004","unstructured":"Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimee R, Klitgaard H (2004) Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson\u2019s disease. J Pharmacol Exp Ther 310(1):386\u2013394. https:\/\/doi.org\/10.1124\/jpet.104.066191","journal-title":"J Pharmacol Exp Ther"},{"issue":"4 pt 1","key":"1869_CR46","doi-asserted-by":"publisher","first-page":"454","DOI":"10.7326\/0003-4819-94-4-454","volume":"94","author":"VW Horadam","year":"1981","unstructured":"Horadam VW, Sharp JG, Smilack JD, McAnalley BH, Garriott JC, Stephens MK, Prati RC, Brater DC (1981) Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 94(4 pt 1):454\u2013458","journal-title":"Ann Intern Med"},{"issue":"14","key":"1869_CR47","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","volume":"78","author":"G Hubsher","year":"2012","unstructured":"Hubsher G, Haider M, Okun MS (2012) Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 78(14):1096\u20131099. https:\/\/doi.org\/10.1212\/WNL.0b013e31824e8f0d","journal-title":"Neurology"},{"issue":"3","key":"1869_CR48","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181\u2013184","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1869_CR49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/pr.111.005678","volume":"65","author":"P Huot","year":"2013","unstructured":"Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM (2013) The pharmacology of l-DOPA-induced dyskinesia in Parkinson\u2019s disease. Pharmacol Rev 65(1):171\u2013222. https:\/\/doi.org\/10.1124\/pr.111.005678","journal-title":"Pharmacol Rev"},{"key":"1869_CR50","first-page":"21","volume":"320","author":"R Jackisch","year":"1992","unstructured":"Jackisch R, Link T, Neufang B, Koch R (1992) Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Int Pharmacodyn Ther 320:21\u201342","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"1869_CR51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuropharm.2013.06.005","volume":"73","author":"TH Johnston","year":"2013","unstructured":"Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM (2013) TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology 73:337\u2013347. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.06.005","journal-title":"Neuropharmacology"},{"issue":"8","key":"1869_CR52","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/jat.1550","volume":"30","author":"V Kaefer","year":"2010","unstructured":"Kaefer V, Semedo JG, Silva Kahl VF, Von Borowsky RG, Gianesini J, Ledur Kist TB, Pereira P, Picada JN (2010) DNA damage in brain cells and behavioral deficits in mice after treatment with high doses of amantadine. J Appl Toxicol 30(8):745\u2013753. https:\/\/doi.org\/10.1002\/jat.1550","journal-title":"J Appl Toxicol"},{"issue":"1","key":"1869_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/WNF.0b013e318204d35c","volume":"34","author":"H Kataoka","year":"2011","unstructured":"Kataoka H, Ueno S (2011) Dropped head associated with amantadine in Parkinson disease. Clin Neuropharmacol 34(1):48\u201349. https:\/\/doi.org\/10.1097\/WNF.0b013e318204d35c","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"1869_CR54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.14802\/jmd.13008","volume":"6","author":"YE Kim","year":"2013","unstructured":"Kim YE, Yun JY, Yang HJ, Kim HJ, Kim MK, Wee WR, Jeon BS (2013) Amantadine induced corneal edema in a patient with primary progressive freezing of gait. J Mov Disord 6(2):34\u201336. https:\/\/doi.org\/10.14802\/jmd.13008","journal-title":"J Mov Disord"},{"issue":"6","key":"1869_CR55","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/mds.25859","volume":"29","author":"WK Ko","year":"2014","unstructured":"Ko WK, Pioli E, Li Q, McGuire S, Dufour A, Sherer TB, Bezard E, Facheris MF (2014) Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson\u2019s disease. Mov Disord 29(6):772\u2013779. https:\/\/doi.org\/10.1002\/mds.25859","journal-title":"Mov Disord"},{"issue":"13","key":"1869_CR56","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1002\/mds.23867","volume":"26","author":"C Kobylecki","year":"2011","unstructured":"Kobylecki C, Hill MP, Crossman AR, Ravenscroft P (2011) Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson\u2019s disease. Mov Disord 26(13):2354\u20132363. https:\/\/doi.org\/10.1002\/mds.23867","journal-title":"Mov Disord"},{"key":"1869_CR57","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17622","author":"M Kong","year":"2017","unstructured":"Kong M, Ba M, Ren C, Yu L, Dong S, Yu G, Liang H (2017) An updated meta-analysis of amantadine for treating dyskinesia in Parkinson\u2019s disease. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.17622","journal-title":"Oncotarget"},{"issue":"9","key":"1869_CR58","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/bms.1200120910","volume":"12","author":"C Koppel","year":"1985","unstructured":"Koppel C, Tenczer J (1985) A revision of the metabolic disposition of amantadine. Biomed Mass Spectrom 12(9):499\u2013501","journal-title":"Biomed Mass Spectrom"},{"issue":"1","key":"1869_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1034\/j.1600-0404.2003.00172.x","volume":"109","author":"A Korchounov","year":"2004","unstructured":"Korchounov A, Kessler KR, Schipper HI (2004) Differential effects of various treatment combinations on cardiovascular dysfunction in patients with Parkinson\u2019s disease. Acta Neurol Scand 109(1):45\u201351","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"1869_CR60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0922-4106(91)90113-V","volume":"206","author":"J Kornhuber","year":"1991","unstructured":"Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206(4):297\u2013300","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"1869_CR61","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/mds.21448","volume":"22","author":"D Koziorowski","year":"2007","unstructured":"Koziorowski D, Friedman A (2007) Levodopa \u201cdrug holiday\u201d with amantadine infusions as a treatment of complications in Parkinson\u2019s disease. Mov Disord 22(7):1033\u20131036. https:\/\/doi.org\/10.1002\/mds.21448","journal-title":"Mov Disord"},{"issue":"2","key":"1869_CR62","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.parkreldis.2007.03.003","volume":"14","author":"S Kubo","year":"2008","unstructured":"Kubo S, Iwatake A, Ebihara N, Murakami A, Hattori N (2008) Visual impairment in Parkinson\u2019s disease treated with amantadine: case report and review of the literature. Parkinsonism Relat Disord 14(2):166\u2013169. https:\/\/doi.org\/10.1016\/j.parkreldis.2007.03.003","journal-title":"Parkinsonism Relat Disord"},{"issue":"15","key":"1869_CR63","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJM199810083391506","volume":"339","author":"AE Lang","year":"1998","unstructured":"Lang AE, Lozano AM (1998) Parkinson\u2019s disease. First of two parts. N Engl J Med 339(15):1044\u20131053","journal-title":"N Engl J Med"},{"key":"1869_CR64","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ajo.2016.08.034","volume":"171","author":"PY Lee","year":"2016","unstructured":"Lee PY, Tu HP, Lin CP, Chang CH, Cheng KC, Lin CC, Hsu SL (2016) Amantadine use as a risk factor for corneal edema: a nationwide cohort study in Taiwan. Am J Ophthalmol 171:122\u2013129. https:\/\/doi.org\/10.1016\/j.ajo.2016.08.034","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1869_CR65","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","volume":"15","author":"E Luginger","year":"2000","unstructured":"Luginger E, Wenning GK, Bosch S, Poewe W (2000) Beneficial effects of amantadine on l-dopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 15(5):873\u2013878","journal-title":"Mov Disord"},{"issue":"1","key":"1869_CR66","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","volume":"194","author":"M Lundblad","year":"2005","unstructured":"Lundblad M, Usiello A, Carta M, Hakansson K, Fisone G, Cenci MA (2005) Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 194(1):66\u201375. https:\/\/doi.org\/10.1016\/j.expneurol.2005.02.002","journal-title":"Exp Neurol"},{"issue":"2","key":"1869_CR67","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0022-3565(25)10406-0","volume":"263","author":"A Lupp","year":"1992","unstructured":"Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ (1992) Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-d-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 263(2):717\u2013724","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1869_CR68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000460814","volume":"9","author":"F Marxreiter","year":"2017","unstructured":"Marxreiter F, Winkler J, Uhl M, Madzar D (2017) A case report of severe delirium after amantadine withdrawal. Case Rep Neurol 9(1):44\u201348. https:\/\/doi.org\/10.1159\/000460814","journal-title":"Case Rep Neurol"},{"issue":"2","key":"1869_CR69","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0022-3565(24)36659-5","volume":"281","author":"H Matsubayashi","year":"1997","unstructured":"Matsubayashi H, Swanson KL, Albuquerque EX (1997) Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons. J Pharmacol Exp Ther 281(2):834\u2013844","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1869_CR70","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/089198879100400306","volume":"4","author":"P McNamara","year":"1991","unstructured":"McNamara P, Durso R (1991) Reversible pathologic jealousy (Othello syndrome) associated with amantadine. J Geriatr Psychiatry Neurol 4(3):157\u2013159","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"11","key":"1869_CR71","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","volume":"56","author":"LV Metman","year":"1999","unstructured":"Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN (1999) Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 56(11):1383\u20131386","journal-title":"Arch Neurol"},{"issue":"1\u20132","key":"1869_CR72","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0006-8993(94)90821-4","volume":"662","author":"K Mizoguchi","year":"1994","unstructured":"Mizoguchi K, Yokoo H, Yoshida M, Tanaka T, Tanaka M (1994) Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-d-aspartate antagonism. Brain Res 662(1\u20132):255\u2013258","journal-title":"Brain Res"},{"issue":"2","key":"1869_CR73","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/0891988708328219","volume":"22","author":"S Montel","year":"2009","unstructured":"Montel S, Bonnet A-M, Bungener C (2009) Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson\u2019s disease. J Geriatr Psychiatry Neurol 22(2):95\u2013102. https:\/\/doi.org\/10.1177\/0891988708328219","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"10","key":"1869_CR74","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00702-002-0694-7","volume":"109","author":"RM Moresco","year":"2002","unstructured":"Moresco RM, Volonte MA, Messa C, Gobbo C, Galli L, Carpinelli A, Rizzo G, Panzacchi A, Franceschi M, Fazio F (2002) New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients: a PET-[(11)C]raclopride study. J Neural Transm 109(10):1265\u20131274. https:\/\/doi.org\/10.1007\/s00702-002-0694-7","journal-title":"J Neural Transm"},{"issue":"5","key":"1869_CR75","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.parkreldis.2008.08.005","volume":"15","author":"N Nishikawa","year":"2009","unstructured":"Nishikawa N, Nagai M, Moritoyo T, Yabe H, Nomoto M (2009) Plasma amantadine concentrations in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 15(5):351\u2013353. https:\/\/doi.org\/10.1016\/j.parkreldis.2008.08.005","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 2","key":"1869_CR76","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1002\/ana.21481","volume":"64","author":"JA Obeso","year":"2008","unstructured":"Obeso JA, Marin C, Rodriguez-Oroz C, Blesa J, Benitez-Temino B, Mena-Segovia J, Rodriguez M, Olanow CW (2008) The basal ganglia in Parkinson\u2019s disease: current concepts and unexplained observations. Ann Neurol 64(Suppl 2):S30\u2013S46. https:\/\/doi.org\/10.1002\/ana.21481","journal-title":"Ann Neurol"},{"key":"1869_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27131","author":"W Oertel","year":"2017","unstructured":"Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ (2017) Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3). Mov Disord. https:\/\/doi.org\/10.1002\/mds.27131","journal-title":"Mov Disord"},{"issue":"8","key":"1869_CR78","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","volume":"28","author":"WC Olanow","year":"2013","unstructured":"Olanow WC, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, Stalevo Reduction in Dyskinesia Evaluation in Parkinson\u2019s Disease I (2013) Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease. Mov Disord 28(8):1064\u20131071. https:\/\/doi.org\/10.1002\/mds.25364","journal-title":"Mov Disord"},{"issue":"4","key":"1869_CR79","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1212\/WNL.0000000000000050","volume":"82","author":"F Ory-Magne","year":"2014","unstructured":"Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destee A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O, Network NS-PC (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82(4):300\u2013307. https:\/\/doi.org\/10.1212\/WNL.0000000000000050","journal-title":"Neurology"},{"issue":"1","key":"1869_CR80","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s100720170054","volume":"22","author":"C Paci","year":"2001","unstructured":"Paci C, Thomas A, Onofrj M (2001) Amantadine for dyskinesia in patients affected by severe Parkinson\u2019s disease. Neurol Sci 22(1):75\u201376","journal-title":"Neurol Sci"},{"key":"1869_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26159","author":"R Pahwa","year":"2015","unstructured":"Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ (2015) Amantadine extended release for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASED study). Mov Disord. https:\/\/doi.org\/10.1002\/mds.26159","journal-title":"Mov Disord"},{"key":"1869_CR82","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0943","author":"R Pahwa","year":"2017","unstructured":"Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ (2017) ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2017.0943","journal-title":"JAMA Neurol"},{"issue":"9","key":"1869_CR83","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1111\/j.1460-9568.2012.08243.x","volume":"36","author":"MA Paquette","year":"2012","unstructured":"Paquette MA, Martinez AA, Macheda T, Meshul CK, Johnson SW, Berger SP, Giuffrida A (2012) Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson\u2019s disease: role of NMDA vs. 5-HT1A receptors. Eur J Neurosci 36(9):3224\u20133234. https:\/\/doi.org\/10.1111\/j.1460-9568.2012.08243.x","journal-title":"Eur J Neurosci"},{"issue":"3","key":"1869_CR84","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1460-9568.1996.tb01228.x","volume":"8","author":"CG Parsons","year":"1996","unstructured":"Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA (1996) Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 8(3):446\u2013454","journal-title":"Eur J Neurosci"},{"key":"1869_CR85","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1468-1331.2005.01096.x","volume":"12","author":"M P\u00e8chevis","year":"2005","unstructured":"P\u00e8chevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-voinet C, Berdeaux G, Ziegler M (2005) Effects of dyskinesias in Parkinson\u2019 s disease on quality of life and health-related costs : a prospective European study. Eur J Neurol 12:956\u2013963","journal-title":"Eur J Neurol"},{"issue":"1\u20132","key":"1869_CR86","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0006-8993(02)02961-X","volume":"949","author":"M Peeters","year":"2002","unstructured":"Peeters M, Page G, Maloteaux JM, Hermans E (2002) Hypersensitivity of dopamine transmission in the rat striatum after treatment with the NMDA receptor antagonist amantadine. Brain Res 949(1\u20132):32\u201341","journal-title":"Brain Res"},{"key":"1869_CR87","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/npjparkd.2016.1","volume":"2","author":"S Perez-Lloret","year":"2016","unstructured":"Perez-Lloret S, Barrantes FJ (2016) Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson\u2019s disease. NPJ Parkinson\u2019s Dis 2:16001\u201316012","journal-title":"NPJ Parkinson\u2019s Dis"},{"issue":"5","key":"1869_CR88","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.parkreldis.2012.01.012","volume":"18","author":"S Perez-Lloret","year":"2012","unstructured":"Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Senard JM, Pavy-Le Traon A, Montastruc JL, Rascol O (2012) Factors related to orthostatic hypotension in Parkinson\u2019s disease. Parkinsonism Relat Disord 18(5):501\u2013505. https:\/\/doi.org\/10.1016\/j.parkreldis.2012.01.012","journal-title":"Parkinsonism Relat Disord"},{"key":"1869_CR89","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13466","author":"S Perez-Lloret","year":"2017","unstructured":"Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destee A, Meissner WG, Tison F, Rascol O, Group CS (2017) l-DOPA-induced dyskinesias, motor fluctuations and Health-related Quality of Life: the COPARK survey. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.13466","journal-title":"Eur J Neurol"},{"issue":"2","key":"1869_CR90","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00006565-199104000-00007","volume":"7","author":"L Pimentel","year":"1991","unstructured":"Pimentel L, Hughes B (1991) Amantadine toxicity presenting with complex ventricular ectopy and hallucinations. Pediatr Emerg Care 7(2):89\u201392","journal-title":"Pediatr Emerg Care"},{"issue":"13","key":"1869_CR91","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Jette N, Frolkis A, Steeves TD (2014) The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 29(13):1583\u20131590. https:\/\/doi.org\/10.1002\/mds.25945","journal-title":"Mov Disord"},{"issue":"5","key":"1869_CR92","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1124\/jpet.115.230201","volume":"90","author":"MV Quaresma","year":"2015","unstructured":"Quaresma MV, Gomes AC, Serruya A, Vendramini DL, Braga L, Bucard AM (2015) Amantadine-induced livedo reticularis\u2014case report. Ann Bras Dermatol 90(5):745\u2013747. https:\/\/doi.org\/10.1124\/jpet.115.230201 ( https:\/\/doi.org\/10.1590\/abd1806-4841.20153394 )","journal-title":"Ann Bras Dermatol"},{"issue":"7","key":"1869_CR93","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/00207454.2012.668727","volume":"122","author":"AQ Rana","year":"2012","unstructured":"Rana AQ, Masroor MS (2012) Patient perception of Levido reticularis due to amantadine. Int J Neurosci 122(7):363\u2013366. https:\/\/doi.org\/10.3109\/00207454.2012.668727","journal-title":"Int J Neurosci"},{"issue":"2","key":"1869_CR94","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1586\/ern.11.203","volume":"12","author":"H Reichmann","year":"2012","unstructured":"Reichmann H, Emre M (2012) Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson\u2019s disease: focus on levodopa\/carbidopa\/entacapone. Expert Rev Neurother 12(2):119\u2013131. https:\/\/doi.org\/10.1586\/ern.11.203","journal-title":"Expert Rev Neurother"},{"issue":"12","key":"1869_CR95","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1038\/sj.npp.1301122","volume":"31","author":"J Reis","year":"2006","unstructured":"Reis J, John D, Heimeroth A, Mueller HH, Oertel WH, Arndt T, Rosenow F (2006) Modulation of human motor cortex excitability by single doses of amantadine. Neuropsychopharmacology 31(12):2758\u20132766. https:\/\/doi.org\/10.1038\/sj.npp.1301122","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1869_CR96","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.parkreldis.2006.07.009","volume":"13","author":"M Reuther","year":"2007","unstructured":"Reuther M, Spottke EA, Klotsche J, Riedel O, Peter H, Berger K, Athen O, Khne-Volland R, Dodel RC (2007) Assessing health-related quality of life in patients with Parkinson\u2019s disease in a prospective longitudinal study. Parkinsonism Relat Disord 13(2):108\u2013114. https:\/\/doi.org\/10.1016\/j.parkreldis.2006.07.009","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1869_CR97","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0304-3940(94)90215-1","volume":"182","author":"J Rohrbacher","year":"1994","unstructured":"Rohrbacher J, Bijak M, Misgeld U (1994) Suppression by memantine and amantadine of synaptic excitation intrastriatally evoked in rat neostriatal slices. Neurosci Lett 182(1):95\u201398","journal-title":"Neurosci Lett"},{"issue":"11","key":"1869_CR98","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s007020070019","volume":"107","author":"E Ruzicka","year":"2000","unstructured":"Ruzicka E, Streitova H, Jech R, Kanovsky P, Roth J, Rektorova I, Mecir P, Hortova H, Bares M, Hejdukova B, Rektor I (2000) Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson\u2019s disease. J Neural Transm (Vienna) 107(11):1297\u20131306. https:\/\/doi.org\/10.1007\/s007020070019","journal-title":"J Neural Transm (Vienna)"},{"issue":"2","key":"1869_CR99","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/0002-9343(84)90728-9","volume":"77","author":"M Sartori","year":"1984","unstructured":"Sartori M, Pratt CM, Young JB (1984) Torsade de Pointe. Malignant cardiac arrhythmia induced by amantadine poisoning. Am J Med 77(2):388\u2013391","journal-title":"Am J Med"},{"issue":"12","key":"1869_CR100","doi-asserted-by":"publisher","first-page":"e15298","DOI":"10.1371\/journal.pone.0015298","volume":"5","author":"H Sawada","year":"2010","unstructured":"Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T, Amantadine Study G (2010) Amantadine for dyskinesias in Parkinson\u2019s disease: a randomized controlled trial. PLoS One 5(12):e15298. https:\/\/doi.org\/10.1371\/journal.pone.0015298","journal-title":"PLoS One"},{"issue":"3","key":"1869_CR101","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF03161197","volume":"4","author":"M Schwartz","year":"2008","unstructured":"Schwartz M, Patel M, Kazzi Z, Morgan B (2008) Cardiotoxicity after massive amantadine overdose. J Med Toxicol 4(3):173\u2013179","journal-title":"J Med Toxicol"},{"key":"1869_CR102","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.nbd.2016.09.001","volume":"96","author":"I Sebastianutto","year":"2016","unstructured":"Sebastianutto I, Maslava N, Hopkins CR, Cenci MA (2016) Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists. Neurobiol Dis 96:156\u2013170","journal-title":"Neurobiol Dis"},{"key":"1869_CR103","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.parkreldis.2017.05.007","volume":"40","author":"M Seier","year":"2017","unstructured":"Seier M, Hiller A (2017) Parkinson\u2019s disease and pregnancy: an updated review. Parkinsonism Relat Disord 40:11\u201317. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.05.007","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"1869_CR104","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S0196-0644(05)82473-4","volume":"19","author":"ER Snoey","year":"1990","unstructured":"Snoey ER, Bessen HA (1990) Acute psychosis after amantadine overdose. Ann Emerg Med 19(6):668\u2013670","journal-title":"Ann Emerg Med"},{"issue":"2","key":"1869_CR105","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","volume":"23","author":"BJ Snow","year":"2000","unstructured":"Snow BJ, Macdonald L, McAuley D, Wallis W (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson\u2019s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 23(2):82\u201385","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"1869_CR106","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/0014-2999(92)90634-G","volume":"213","author":"JC Stoof","year":"1992","unstructured":"Stoof JC, Booij J, Drukarch B, Wolters EC (1992) The anti-parkinsonian drug amantadine inhibits the N-methyl-d-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 213(3):439\u2013443","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1869_CR107","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0361-9230(96)00211-0","volume":"41","author":"T Takahashi","year":"1996","unstructured":"Takahashi T, Yamashita H, Zhang YX, Nakamura S (1996) Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res Bull 41(6):363\u2013367","journal-title":"Brain Res Bull"},{"issue":"1","key":"1869_CR108","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/jnnp.2004.036558","volume":"75","author":"A Thomas","year":"2004","unstructured":"Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 75(1):141\u2013143","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"1869_CR109","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/ana.22029","volume":"68","author":"A Thomas","year":"2010","unstructured":"Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68(3):400\u2013404. https:\/\/doi.org\/10.1002\/ana.22029","journal-title":"Ann Neurol"},{"issue":"1","key":"1869_CR110","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3109\/02699059509004571","volume":"9","author":"R Reekum Van","year":"1995","unstructured":"Van Reekum R, Bayley M, Garner S, Burke IM, Fawcett S, Hart A, Thompson W (1995) N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 9(1):49\u201353","journal-title":"Brain Inj"},{"issue":"1\u20133","key":"1869_CR111","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF01345246","volume":"14","author":"L Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, Blanchet PJ, van den Munckhof P, Chase TN (1998a) Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease. Amino Acids 14(1\u20133):75\u201382","journal-title":"Amino Acids"},{"issue":"5","key":"1869_CR112","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","volume":"50","author":"L Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998b) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease. Neurology 50(5):1323\u20131326","journal-title":"Neurology"},{"issue":"1","key":"1869_CR113","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s100720170067","volume":"22","author":"MA Volonte","year":"2001","unstructured":"Volonte MA, Moresco RM, Gobbo C, Messa C, Carpinelli A, Rizzo G, Comi G, Fazio F (2001) A PET study with [11-C]raclopride in Parkinson\u2019s disease: preliminary results on the effect of amantadine on the dopaminergic system. Neurol Sci 22(1):107\u2013108","journal-title":"Neurol Sci"},{"issue":"12","key":"1869_CR114","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/S1474-4422(09)70287-X","volume":"8","author":"V Voon","year":"2009","unstructured":"Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E (2009) Chronic dopaminergic stimulation in Parkinson\u2019s disease: from dyskinesias to impulse control disorders. Lancet Neurol 8(12):1140\u20131149. https:\/\/doi.org\/10.1016\/S1474-4422(09)70287-X","journal-title":"Lancet Neurol"},{"issue":"6","key":"1869_CR115","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.22164","volume":"68","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68(6):963\u2013968. https:\/\/doi.org\/10.1002\/ana.22164","journal-title":"Ann Neurol"},{"issue":"10","key":"1869_CR116","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/mds.23034","volume":"25","author":"E Wolf","year":"2010","unstructured":"Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson\u2019s disease. Mov Disord 25(10):1357\u20131363. https:\/\/doi.org\/10.1002\/mds.23034","journal-title":"Mov Disord"},{"issue":"12","key":"1869_CR117","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2165\/00003495-200464120-00003","volume":"64","author":"UA Zifko","year":"2004","unstructured":"Zifko UA (2004) Management of fatigue in patients with multiple sclerosis. Drugs 64(12):1295\u20131304","journal-title":"Drugs"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-018-1869-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1869-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1869-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T12:42:43Z","timestamp":1751460163000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-018-1869-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":117,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["1869"],"URL":"https:\/\/doi.org\/10.1007\/s00702-018-1869-1","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"18 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}